Oops!
The page you are looking for no longer exists. Perhaps starting from the site's homepage will get you on the right track.
Try typing in what you are looking for:
Recent Posts:
- Leerink Partners Serves as Lead-Left Bookrunner for Edgewise Therapeutics’ (Nasdaq: EWTX) $240 Million Follow-On Offering
- Leerink Partners Serves as Joint Bookrunner for Immatics’ (Nasdaq: IMTX) $175 Million Follow-On Offering
- Leerink Partners Serves as Joint Bookrunner for Viridian Therapeutics’ (Nasdaq: VRDN) $150 Million Follow-On Offering
- Leerink Partners Serves as Exclusive Financial Advisor to Zentalis Pharmaceuticals (Nasdaq: ZNTL) on its Global Licensing Agreement with Immunome (Nasdaq: IMNM)
- Leerink Partners Serves as Joint Bookrunner for Keros Therapeutics’ (Nasdaq: KROS) $140 Million Follow-On Offering
- Leerink Partners Serves as Lead Placement Agent for Immunic’s (Nasdaq: IMUX) Up to $240 Million Private Placement
- Leerink Partners Strengthens Healthcare Services and Technology Team with Hire of Philip Boyd
- Leerink Partners Serves as Exclusive Financial Advisor for SQZ Biotechnologies’ Asset Sale to STEMCELL Technologies
- Leerink Partners Serves as Exclusive Financial Advisor for Theseus Pharmaceuticals’ (Nasdaq: THRX) Proposed Acquisition by Concentra Biosciences, LLC
- Leerink Partners Serves as Joint Bookrunner for AC Immune SA’s (Nasdaq: ACIU) $50 Million Follow-On Offering